C4 Therapeutics Appoints New Chief Medical Officer
Ticker: CCCC · Form: 8-K · Filed: Apr 14, 2025 · CIK: 1662579
| Field | Detail |
|---|---|
| Company | C4 Therapeutics, Inc. (CCCC) |
| Form Type | 8-K |
| Filed Date | Apr 14, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, management-change
TL;DR
C4 Therapeutics names Dr. Adam Schlegel as new CMO, effective April 10th.
AI Summary
C4 Therapeutics, Inc. announced on April 14, 2025, that its Board of Directors appointed Dr. Adam R. Schlegel as Chief Medical Officer, effective April 10, 2025. Dr. Schlegel previously served as Senior Vice President, Clinical Development at the company. This appointment is part of the company's ongoing efforts in clinical development.
Why It Matters
The appointment of a new Chief Medical Officer is a key leadership change that could impact the company's strategic direction and execution of its clinical trials.
Risk Assessment
Risk Level: low — This filing reports a routine executive appointment, not a significant financial event or strategic shift.
Key Players & Entities
- C4 Therapeutics, Inc. (company) — The reporting company
- Dr. Adam R. Schlegel (person) — Newly appointed Chief Medical Officer
- April 10, 2025 (date) — Effective date of appointment
- April 14, 2025 (date) — Date of report
FAQ
Who is the new Chief Medical Officer of C4 Therapeutics?
Dr. Adam R. Schlegel has been appointed as the new Chief Medical Officer of C4 Therapeutics.
When did Dr. Adam R. Schlegel's appointment become effective?
The appointment of Dr. Adam R. Schlegel became effective on April 10, 2025.
What was Dr. Schlegel's previous role at C4 Therapeutics?
Prior to his appointment as CMO, Dr. Schlegel served as Senior Vice President, Clinical Development at C4 Therapeutics.
What is the primary business of C4 Therapeutics?
C4 Therapeutics, Inc. is involved in Biological Products (No Diagnostic Substances).
What is the SEC file number for C4 Therapeutics?
The SEC file number for C4 Therapeutics is 001-39567.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 14, 2025 by Dr. Adam R. Schlegel regarding C4 Therapeutics, Inc. (CCCC).